



15 February 2023

OPL RIGHTS ISSUE RESULTS

Melbourne, Australia – Opyl Limited (ASX:OPL) (Company) is pleased to advise that:

- The Entitlement Offer closed on Monday, 13 February 2023 (Closing Date), raising \$355,768 from Eligible Shareholders of the Company.
- The Shortfall under the Entitlement Offer is 4,154,059 shares (which could raise up to \$124,622), which the Company can allocate and issue at the Board's discretion within 3 months of the Closing Date.
- The Company has received interest for the available shortfall shares and will continue to keep the market informed of any updates.

The Company has accepted applications from Eligible Shareholders for 11,858,954 shares at an issue price of A\$0.03, raising \$355,768 (before costs). This includes applications for additional shares from Eligible Shareholders, which have been accepted by the Company. The total shortfall amount is \$124,622 based on the maximum subscription amount of \$480,390.

Accordingly, the shortfall under the Entitlement Offer equates to 4,154,059 shares. As disclosed in the Company's offer booklet, the Board reserves its right to allot the shortfall at its discretion within 3 months of the Closing Date at a price not less than A\$0.03 per share. As of this announcement, the Company remains in discussion with a number of parties and broker in relation to the available shortfall shares.

The Company would like to thank its shareholders for supporting the Entitlement Offer.

The following table sets out a summary of the outcome from the Entitlement Offer:

Description	Number of New Shares
Maximum number of shares offered under the Entitlement Offer	16,013,013
Total application accepted by the Company from Eligible Shareholders	11,858,954
Remaining available shortfall	4,154,059

The issue of shares under the Entitlement Offer to the Eligible Shareholders will take place on 15 February 2023.

The Board has authorised this announcement for release to the ASX.



-ENDS-

For media enquiries: info@opyl.ai

For investor enquiries: info@opyl.ai

www.opyl.ai www.opin.ai

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions
- clinical trial predictive analytics and protocol design
- deep social media insights and analysis

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook